Navigation Links
European Society of Human Reproduction & Embryology 24th annual meeting
Date:4/14/2008

Reproductive medicine is one of the most exciting scientific and clinical areas. Every month brings announcements of research developments, medical firsts, new rulings by regulatory bodies, or ethical controversies often sparking heated debate among practitioners in the field themselves, as well as ethicists, legislators, the media and the public.

ESHREs annual meeting is the forum where more than 5,000 of the worlds leading experts in reproductive medicine gather to give the first public presentation of their latest research findings and to discuss issues that are presenting law-makers and ethicists with some of the most challenging problems and difficult decisions currently facing society.

We welcome the media to the meeting. All sessions are open to journalists and registration is free to bona fide journalists on presentation of official press credentials. A media centre with computers, fax, printing, photocopying and free local and international telephone facilities and internet connections will be available.

English and Spanish-speaking press office staff will be on hand to assist you. But please note that the official conference language is English. There are no simultaneous translations.

To register: download the form at http://www.eshre.com/emc.asp?pageId=294 and fax, with a photocopy of your press credentials, to:

Sarah de Potter, ESHRE communications manager
Fax: +32/2/269 56 00
Tel: +32/473/ 35 33 81
Email: sarah@eshre.com

For more information contact Sarah de Potter or Mary Rice (mary@mrcommunication.org; tel: +33 (0)3 21825444) or visit the ESHRE website: http://www.eshre.com

Registration in advance is recommended, but you may register on site providing that you produce press credential
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. Launch of second European Cancer Research Funding survey
7. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
8. Pharsight to Host European Software Conference
9. OmniGuide Begins European Commercialization
10. Paving the way for future pan-European clinical trials
11. US, European cancer educators gather in Alabama for meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... A series of new guidelines for cardiac specialists has ... receive a mechanical heart-pumping device. "The new guidelines ... circulatory support device, and how early in the process ... device," says Jeffrey A. Morgan, M.D., associate director of ...
... 15 (HealthDay News) -- U.S. scientists who completed the ... will improve the ability to diagnose and treat the ... an approach that decodes the 1 to 2 percent ... team, led by researchers at the U.S. National Institutes ...
... Kobe City University of Foreign Studies surveyed and questioned Twitter ... on the social media site two weeks after the Tohoku ... determine what benefits such a system can bring to people ... news. The researchers found that people in directly affected ...
... Meat and poultry sold in the United States is widely ... bacteria that can cause serious illnesses in humans, a new ... to S. aureus range from mild skin infections ... In the new nationwide study, researchers analyzed 136 samples ...
... FRIDAY, April 15 (HealthDay News) -- Teens who start school ... crashes, a new study finds. But starting the school ... reduce impulsiveness, another study finds. In 2008, the weekday ... Va., was about 41 percent higher than for the same ...
... when occurring with hay fever, are nine times more likely ... reveals. The study was conducted by the University ... and Monash University. Published online in the ... reported on evidence from a clinical study of around 1400 ...
Cached Medicine News:Health News:Scientists Spot Key Gene Mutations in Melanoma 2Health News:Twitter and natural disasters 2Health News:Twitter and natural disasters 3Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 2Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 3Health News:Early School Start Tied to More Teen Crashes: Study 2Health News:Childhood eczema and hay fever leads to adult allergic asthma 2
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (Nasdaq: ERES ) announced today that it will ... May 2, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
... April 15, 2011 Atrium Medical Corporation has provided ... Atrium University, at www.AtriumU.com .  "Atrium has been ... for our customers," said Jeff McGill, Senior Vice President ... guidelines for companies, interactions with nurses and physicians, we ...
Cached Medicine Technology:ERT Reports First Quarter 2011 Operating Results on May 2, 2011 2Atrium Provides Grant to Establish Education Web Site at AtriumU.com 2
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... Bridge assembly allows internal or ... cooling coil allows rapid cool-down ... within approximately 10 C of ... is only 5.7 inches wideideal ...
Inquire...
Medicine Products: